-
FDA Approves Takeda’s Eohilia as First Oral Therapy for Eosinophilic Esophagitis in Patients Aged 11 and Up
•
The U.S. Food and Drug Administration (FDA) has granted approval to Takeda Pharmaceutical Company (TYO: 4502)’s Eohilia (budesonide oral suspension) for the treatment of eosinophilic esophagitis (EoE). This marks Eohilia as the first and currently only oral therapy available for EoE patients aged 11 and older. Previously, Novartis (NYSE: NVS)’s…
-
Roche’s Piasky (Crovalimab) Secures NMPA Approval for Untreated Paroxysmal Nocturnal Hemoglobinuria
•
The National Medical Products Administration (NMPA) has granted marketing approval to Swiss pharmaceutical giant Roche (SWX: ROG) for Piasky (crovalimab) under priority review status. This approval is specifically for the treatment of adult and adolescent patients aged 12 and older with paroxysmal nocturnal hemoglobinuria who have not previously received treatment…
-
Roche Secures NMPA Approval for Rozlytrek to Treat Pediatric NTRK Fusion-Positive Tumors
•
Swiss pharmaceutical giant Roche (SWX: ROG) has received a new indication approval from the National Medical Products Administration (NMPA) for its drug Rozlytrek (entrectinib). The approval allows the treatment of pediatric patients aged at least one month with NTRK fusion-positive solid tumors. Entrectinib is a TRK/ROS1 tyrosine kinase inhibitor known…
-
Akeso Biopharma to Acquire 35% Stake in AD Pharmaceuticals for RMB 267 Million
•
Akeso Biopharma (HKG: 9926) is poised to acquire a 35% stake in AD Pharmaceuticals Co., Ltd., a joint venture with Dawnrays Pharmaceutical (HKG: 2348), for a total consideration of RMB 267 million (USD 37.5 million). Upon completion of the transaction, AD Pharmaceuticals will become a wholly-owned subsidiary of Akeso. AD…
-
AstraZeneca Reports 6% Revenue Growth in 2023, Driven by Oncology and Diabetes Drug Sales
•
AstraZeneca (AZ; NASDAQ: AZN), the UK-based multinational, reported its financial results for 2023 this week, revealing a 6% year-on-year increase in annual global revenues, reaching USD 45.8 billion at constant exchange rates. Oncology revenue surged by 21%, while cardiovascular, renal, and metabolism (CVRM) sales rose 18%. Respiratory and immunology (R&I)…
-
I-Mab to Become U.S.-Based Biotech, Divesting All China Assets for Up to $80 Million
•
I-Mab (NASDAQ: IMAB), a biotech company transitioning to a U.S.-based entity, has announced plans to divest all its assets in China. The company has entered into agreements with I-Mab Biopharma (Hangzhou) Co., Ltd and a consortium of Chinese investors to sell its operations in China, including its remaining equity interest…
-
AbbVie Expands Licensing Agreement for Innovative sCAR-T Platform with Scripps Research
•
AbbVie (NYSE: ABBV) has expanded its collaboration with Scripps Research’s Calibr-Skaggs Institute, securing licensing rights to the institute’s investigational switchable CAR-T (sCAR-T) platform, which has shown promising early-stage results. The agreement entails an upfront payment, along with potential milestone payments and royalties, allowing AbbVie to access the program for up…
-
AstraZeneca Announces $300 Million Investment in Next-Gen Cell Therapies Manufacturing in the U.S.
•
AstraZeneca (AZ; NASDAQ: AZN), headquartered in the UK, has announced a significant investment of $300 million to establish a next-generation cell therapies manufacturing facility in the United States. This new site is set to enhance support for global clinical trials and facilitate local product launches. This strategic move follows AstraZeneca’s…
